A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
2015 ◽
Vol 138
(3)
◽
pp. 513-518
◽
Kathleen N. Moore
◽
Michael W. Sill
◽
Meaghan E. Tenney
◽
Christopher J. Darus
◽
David Griffin
◽
...
2015 ◽
Vol 137
◽
pp. 24
◽
K.N. Moore
◽
M. Sill
◽
M.E. Tenney
◽
C.J. Darus
◽
D. Griffin
◽
...
1984 ◽
Vol 7
(3)
◽
pp. 261-264
◽
J. Tate Thigpen
◽
John A. Blessing
◽
James C. Arseneau
◽
Howard D. Homesley
1988 ◽
Vol 31
(3)
◽
pp. 435-438
◽
J. Tate Thigpen
◽
John A. Blessing
◽
Harrison Ball
◽
Parviz Hanjani
◽
Alberto Manetta
◽
...
1989 ◽
Vol 29
(3)
◽
pp. 282-282
JT Thigpen
◽
JA Blessing
◽
H Ball
◽
P Hanjani
◽
A Manetta
◽
...
2010 ◽
Vol 2010
◽
pp. 69-70
2004 ◽
Vol 93
(1)
◽
pp. 144-148
◽
Farr Nezhat
◽
Scott Wadler
◽
Franco Muggia
◽
John Mandeli
◽
Gary Goldberg
◽
...
2007 ◽
Vol 2007
◽
pp. 82-83
David Kushner
◽
Ryan Spencer
1989 ◽
Vol 161
(2)
◽
pp. 309-312
◽
Gregory P. Sutton
◽
John A. Blessing
◽
Neil Rosenshein
◽
Guy Photopulos
◽
Philip J. DiSaia
2011 ◽
Vol 121
(3)
◽
pp. 455-461
◽
Lydia Usha
◽
Michael W. Sill
◽
Kathleen M. Darcy
◽
Doris M. Benbrook
◽
Jean A. Hurteau
◽
...
Close
Export Citation Format
Close
Share Document
Close